TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has provided an announcement.
Clover Biopharmaceuticals Ltd. announced positive preliminary results from Phase I clinical trials for its combination vaccines targeting RSV, hMPV, and PIV3, as well as for RSV re-vaccination in older adults. The trials demonstrated promising immune responses and safety profiles, with plans to advance to Phase II trials in 2026. These developments could enhance Clover’s positioning in the vaccine market and offer new options for older adults, potentially impacting stakeholders positively.
The most recent analyst rating on (HK:2197) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on developing innovative vaccines and biologic therapies. The company leverages its proprietary Trimer-Tag platform technology to create combination vaccines targeting respiratory viruses, including RSV, hMPV, and PIV3.
Average Trading Volume: 22,795,260
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.63B
See more data about 2197 stock on TipRanks’ Stock Analysis page.